Editorials

Intracoronary stents

BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7062.892 (Published 12 October 1996) Cite this as: BMJ 1996;313:892
  1. Neal G Uren, Visiting cardiologist,
  2. Nicolas Af Chronos, Assistant professor of medicine
  1. Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
  2. Andreas Gruntzig Cardiovascular Center, Emory University Hospital, Atlanta, GA 30323, USA

    Reducing restenosis after angioplasty

    Coronary angioplasty has become an accepted treatment for coronary disease, with over 13 000 procedures performed in Britain in 1995 (410 000 in the United States). During the 1980s the overall primary success rate of angioplasty was 90%, with complications such as myocardial infarction, emergency surgery, and death occurring in up to 0.9%, 3.2%, and 1.2% of cases respectively, depending on the extent of coronary disease.1 However, even with recent improvements in angioplasty technology, percutaneous revascularisation techniques have been limited by restenosis, predominantly through neointimal hyperplasia, but also through vessel shrinkage (adverse remodelling).2 Angiographic restenosis occurs in 30–50% of cases by six months' follow up, with clinical (symptomatic) restenosis in most of these cases.1 With no pharmacological treatment consistently reducing the restenosis rate in randomised studies, there has been an increased need for reintervention with further angioplasty or bypass surgery in 44% over the first three years of follow up, offsetting the initial savings in cost …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe